Transplantation Reports最新文献_第3页

Targeting Ischemia-reperfusion injury in liver transplant rejuvenation 肝移植返老还童中的靶向缺血再灌注损伤

Q4 Medicine

Transplantation Reports

Pub Date : 2025-06-01 Epub Date: 2025-02-26 DOI: 10.1016/j.tpr.2025.100176

Kenneth J. Dery, Fady Kaldas, Jerzy W. Kupiec-Weglinski

Background

Hepatic ischemia-reperfusion injury (HIRI) is a multifaceted pathophysiological process involving a cascade of interconnected cellular events. The initial ischemic stress, followed by the reestablishment of blood circulation to the liver, triggers a feed-forward innate immune-driven response that exacerbates the hepatocellular injury. HIRI poses a significant clinical challenge in liver transplantation (LT), as it can result in tissue damage, organ dysfunction, and poor clinical outcomes.

Methods and results

This review highlights current key issues in HIRI translational research, as revealed by recent bibliometric studies. It examines the mechanisms that facilitate homeostatic regulation after HIRI. Additionally, it addresses refined pharmacological strategies aimed at mitigating oxidative stress and inflammation. Hot topic areas in HIRI research include autophagy, donation after circulatory death, and NLRP3-dependent inflammasome activation following LT. New pharmacological agents, such as anti-oxidative compounds, metabolic modulators, and plant-derived compounds, are being explored to influence inflammatory responses. There is a strong clinical emphasis on broadening the donor pool by utilizing marginal donor grafts and advanced machine perfusion techniques. Enhancing translational research through the development of human-relevant organoids or ex vivo liver perfusion systems is essential for connecting laboratory discoveries with clinical practices in life-saving surgical procedures.

Conclusion

A comprehensive approach that emphasizes the regulatory mechanisms of cellular responses to oxygen stress and immune cell activation, alongside innovative donor organ preservation, like machine perfusion, will shape the future direction of HIRI research by enhancing graft viability and revitalizing suboptimal donor organs.

背景肝脏缺血再灌注损伤（HIRI）是一个多方面的病理生理过程，涉及一连串相互关联的细胞事件。最初的缺血应激，随后肝脏血液循环的重建，引发了前馈性先天性免疫驱动反应，加剧了肝细胞损伤。肝细胞损伤是肝移植（LT）的一个重大临床挑战，因为它可能导致组织损伤、器官功能障碍和不良的临床结果。它探讨了促进 HIRI 后体内平衡调节的机制。此外，它还探讨了旨在减轻氧化应激和炎症的精细药理策略。HIRI 研究的热门话题领域包括自噬、循环死亡后的捐赠以及 LT 后 NLRP3 依赖性炎性体的激活。目前正在探索新的药理制剂，如抗氧化化合物、代谢调节剂和植物提取的化合物，以影响炎症反应。临床上非常重视利用边缘供体移植物和先进的机器灌注技术来扩大供体库。通过开发与人体相关的器官组织或体内外肝脏灌注系统来加强转化研究，对于将实验室发现与挽救生命的外科手术的临床实践联系起来至关重要。结论强调细胞对氧应激和免疫细胞激活反应的调控机制的综合方法，以及创新的供体器官保存方法（如机器灌注），将通过提高移植物的存活率和活化次优供体器官来塑造未来的 HIRI 研究方向。

{"title":"Targeting Ischemia-reperfusion injury in liver transplant rejuvenation","authors":"Kenneth J. Dery, Fady Kaldas, Jerzy W. Kupiec-Weglinski","doi":"10.1016/j.tpr.2025.100176","DOIUrl":"10.1016/j.tpr.2025.100176","url":null,"abstract":"<div><h3>Background</h3><div>Hepatic ischemia-reperfusion injury (HIRI) is a multifaceted pathophysiological process involving a cascade of interconnected cellular events. The initial ischemic stress, followed by the reestablishment of blood circulation to the liver, triggers a feed-forward innate immune-driven response that exacerbates the hepatocellular injury. HIRI poses a significant clinical challenge in liver transplantation (LT), as it can result in tissue damage, organ dysfunction, and poor clinical outcomes.</div></div><div><h3>Methods and results</h3><div>This review highlights current key issues in HIRI translational research, as revealed by recent bibliometric studies. It examines the mechanisms that facilitate homeostatic regulation after HIRI. Additionally, it addresses refined pharmacological strategies aimed at mitigating oxidative stress and inflammation. Hot topic areas in HIRI research include autophagy, donation after circulatory death, and NLRP3-dependent inflammasome activation following LT. New pharmacological agents, such as anti-oxidative compounds, metabolic modulators, and plant-derived compounds, are being explored to influence inflammatory responses. There is a strong clinical emphasis on broadening the donor pool by utilizing marginal donor grafts and advanced machine perfusion techniques. Enhancing translational research through the development of human-relevant organoids or ex vivo liver perfusion systems is essential for connecting laboratory discoveries with clinical practices in life-saving surgical procedures.</div></div><div><h3>Conclusion</h3><div>A comprehensive approach that emphasizes the regulatory mechanisms of cellular responses to oxygen stress and immune cell activation, alongside innovative donor organ preservation, like machine perfusion, will shape the future direction of HIRI research by enhancing graft viability and revitalizing suboptimal donor organs.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 2","pages":"Article 100176"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current state of artificial intelligence in liver transplantation 人工智能在肝移植中的应用现状

Q4 Medicine

Transplantation Reports

Pub Date : 2025-06-01 Epub Date: 2025-02-10 DOI: 10.1016/j.tpr.2025.100173

Ashley E. Montgomery , Abbas Rana

Over the past few decades, substantial progress has been made in the field of liver transplantation. Yet, challenges remain in the field due to an increasing organ allograft shortage as well as significant waitlist mortality. With these challenges, organ allocation policies have been developed and are constantly being modified to result in more efficient organ allocation. One tool that has been explored to improve the field of liver transplantation is artificial intelligence, which is an umbrella term for techniques such as machine learning and deep learning. This review article explores the use of artificial intelligence in the field of liver transplantation. Specifically, studies have shown potential applications of artificial intelligence in improving waitlist mortality models, assessing allograft characteristics, using large language models for research question development and patient education, developing post-transplant models, as well as predicting multiple risk factors such as cardiovascular disease, infection, graft failure, malignancy, graft fibrosis, and pneumonia. However, even with these studies, several limitations for the use of artificial intelligence exist such as biased data sets leading to biased model development, lack of extensive validation of the artificial intelligence models, and the need for large datasets for model development. With additional studies evaluating the use of artificial intelligence and wide-scale validation of these studies highlighted, the use of artificial intelligence may transform the field of transplantation in the future.

在过去的几十年里，肝移植领域取得了实质性的进展。然而，由于同种异体器官移植短缺的增加以及大量的等待者死亡率，该领域仍然存在挑战。面对这些挑战，器官分配政策已经制定，并不断修改，以实现更有效的器官分配。人工智能是改善肝移植领域的一种工具，它是机器学习和深度学习等技术的总称。本文综述了人工智能在肝移植领域的应用。具体而言，研究表明人工智能在以下方面的潜在应用：改进等候名单死亡率模型、评估同种异体移植物特征、使用大型语言模型进行研究问题开发和患者教育、开发移植后模型，以及预测多种危险因素，如心血管疾病、感染、移植物衰竭、恶性肿瘤、移植物纤维化和肺炎。然而，即使有了这些研究，人工智能的使用也存在一些限制，例如有偏见的数据集导致有偏见的模型开发，缺乏对人工智能模型的广泛验证，以及模型开发需要大型数据集。随着更多评估人工智能应用的研究和这些研究的大规模验证，人工智能的应用可能会在未来改变移植领域。

{"title":"Current state of artificial intelligence in liver transplantation","authors":"Ashley E. Montgomery , Abbas Rana","doi":"10.1016/j.tpr.2025.100173","DOIUrl":"10.1016/j.tpr.2025.100173","url":null,"abstract":"<div><div>Over the past few decades, substantial progress has been made in the field of liver transplantation. Yet, challenges remain in the field due to an increasing organ allograft shortage as well as significant waitlist mortality. With these challenges, organ allocation policies have been developed and are constantly being modified to result in more efficient organ allocation. One tool that has been explored to improve the field of liver transplantation is artificial intelligence, which is an umbrella term for techniques such as machine learning and deep learning. This review article explores the use of artificial intelligence in the field of liver transplantation. Specifically, studies have shown potential applications of artificial intelligence in improving waitlist mortality models, assessing allograft characteristics, using large language models for research question development and patient education, developing post-transplant models, as well as predicting multiple risk factors such as cardiovascular disease, infection, graft failure, malignancy, graft fibrosis, and pneumonia. However, even with these studies, several limitations for the use of artificial intelligence exist such as biased data sets leading to biased model development, lack of extensive validation of the artificial intelligence models, and the need for large datasets for model development. With additional studies evaluating the use of artificial intelligence and wide-scale validation of these studies highlighted, the use of artificial intelligence may transform the field of transplantation in the future.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 2","pages":"Article 100173"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing drug-drug interactions of Tacrolimus with Fluconazole and/or Verapamil and developing the predictive model for Tacrolimus concentrations in kidney transplant recipients 评估他克莫司与氟康唑和/或维拉帕米的药物相互作用，并建立肾移植受者他克莫司浓度的预测模型

Q4 Medicine

Transplantation Reports

Pub Date : 2025-06-01 Epub Date: 2025-02-24 DOI: 10.1016/j.tpr.2025.100175

Mingkwan Na Takuathung , Kajohnsak Noppakun , Chotiwit Sakuludomkan , Nahathai Dukaew , Nuttapong Chailungkar , Naruemon Suyayai , Nut Koonrungsesomboon

Maintaining optimal tacrolimus serum concentrations is crucial for kidney transplant recipients due to its narrow therapeutic window and pharmacokinetic variability. The use of CYP3A4/5 inhibitors, such as fluconazole and verapamil, can increase tacrolimus serum concentrations. Understanding these interactions is vital for predicting and optimizing tacrolimus levels. This study aimed to investigate the impact of co-administering fluconazole, verapamil, or their combination on tacrolimus concentration/dose (C/D) in kidney transplant recipients and develop a predictive model for these scenarios. This retrospective study involved kidney transplant recipients treated with tacrolimus and co-administered fluconazole and/or verapamil. The Generalized Estimating Equations (GEE) approach was used to explore predictive variables associated with tacrolimus C/D. A total of 177 kidney transplant recipients were included. Repeated measure correlation analysis revealed positive correlations between tacrolimus C/D and dosages of fluconazole (b = 0.37, 95 % CI = 0.29 to 0.45, p < 0.001) and verapamil (b = 0.15, 95 % CI = 0.07 to 0.23, p < 0.001). This study offers a predictive model for optimizing tacrolimus levels when fluconazole and/or verapamil are co-administered in kidney transplant recipients.

维持最佳的他克莫司血清浓度对于肾移植受者来说是至关重要的，因为它具有狭窄的治疗窗口和药代动力学变异性。使用CYP3A4/5抑制剂，如氟康唑和维拉帕米，可增加他克莫司的血清浓度。了解这些相互作用对于预测和优化他克莫司水平至关重要。本研究旨在探讨氟康唑、维拉帕米或两者联合使用对肾移植受者他克莫司浓度/剂量（C/D）的影响，并为这些情况建立预测模型。这项回顾性研究涉及接受他克莫司和氟康唑和/或维拉帕米联合治疗的肾移植受者。采用广义估计方程（GEE）方法探讨与他克莫司C/D相关的预测变量。共纳入177名肾移植受者。重复测量相关性分析显示他克莫司C/D与氟康唑剂量呈正相关(b = 0.37, 95% CI = 0.29 ~ 0.45, p <；0.001)和维拉帕米(b = 0.15, 95% CI = 0.07 ~ 0.23, p <；0.001)。本研究提供了一个预测模型，用于优化氟康唑和/或维拉帕米在肾移植受者中联合应用时他克莫司的水平。

{"title":"Assessing drug-drug interactions of Tacrolimus with Fluconazole and/or Verapamil and developing the predictive model for Tacrolimus concentrations in kidney transplant recipients","authors":"Mingkwan Na Takuathung , Kajohnsak Noppakun , Chotiwit Sakuludomkan , Nahathai Dukaew , Nuttapong Chailungkar , Naruemon Suyayai , Nut Koonrungsesomboon","doi":"10.1016/j.tpr.2025.100175","DOIUrl":"10.1016/j.tpr.2025.100175","url":null,"abstract":"<div><div>Maintaining optimal tacrolimus serum concentrations is crucial for kidney transplant recipients due to its narrow therapeutic window and pharmacokinetic variability. The use of CYP3A4/5 inhibitors, such as fluconazole and verapamil, can increase tacrolimus serum concentrations. Understanding these interactions is vital for predicting and optimizing tacrolimus levels. This study aimed to investigate the impact of co-administering fluconazole, verapamil, or their combination on tacrolimus concentration/dose (C/D) in kidney transplant recipients and develop a predictive model for these scenarios. This retrospective study involved kidney transplant recipients treated with tacrolimus and co-administered fluconazole and/or verapamil. The Generalized Estimating Equations (GEE) approach was used to explore predictive variables associated with tacrolimus C/D. A total of 177 kidney transplant recipients were included. Repeated measure correlation analysis revealed positive correlations between tacrolimus C/D and dosages of fluconazole (<em>b</em> = 0.37, 95 % CI = 0.29 to 0.45, <em>p</em> < 0.001) and verapamil (<em>b</em> = 0.15, 95 % CI = 0.07 to 0.23, <em>p</em> < 0.001). This study offers a predictive model for optimizing tacrolimus levels when fluconazole and/or verapamil are co-administered in kidney transplant recipients.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 2","pages":"Article 100175"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 vaccine evaluation among solid organ transplant recipients at a single academic center 单一学术中心实体器官移植受者COVID-19疫苗评估

Q4 Medicine

Transplantation Reports

Pub Date : 2025-06-01 Epub Date: 2025-02-21 DOI: 10.1016/j.tpr.2025.100174

Kristen Lay , Marina Feffer , David Slade , Fritzie S. Albarillo

Background

Solid organ transplant recipients (SOTRs) may have a higher risk of serious disease and death due to COVID-19. It is necessary to determine the main motivators and demotivators for SOTRs to receive COVID-19 vaccinations to improve patient education.

Methods

A voluntary and anonymous survey was created using questions adopted from the Center for Disease Control COVID-19 Vaccine Confidence: Rapid Community Assessment. Questions included demographics, vaccination status and opinions in multiple choice and free response format. The survey was distributed in July 2023 and was open for one month.

Results

A total of 127 SOTRs responded which included patients 18 years and older who received one of the following transplants: heart (12.6 %), lung(s) (37.01 %), liver (31.5 %), kidney (11.81 %), and liver and kidney (7.09 %). The overwhelming majority of respondents received a primary vaccination series (97.64 %). Among the vaccinated, 68.55 % received a bivalent booster vaccination and 32.28 % have received a second booster vaccination. The greatest motivating factors among vaccinated were “protecting my health” (84.68 %) “protecting the health of family and friends” (66.13 %), and “to protect the health of the community” (36.29 %). Only 3 SOTRs were unvaccinated, all of whom reported that they felt the vaccine was unsafe.

Conclusion

While the overwhelming majority of SOTRs were vaccinated against COVID-19 to protect their health and the health of others, a minority have hesitations about receiving booster vaccinations. Targeting patient education towards these concerns will improve the protection of the SOTR community.

背景：实体器官移植受者（SOTRs）因COVID-19可能有更高的严重疾病和死亡风险。有必要确定sotr接受COVID-19疫苗接种的主要激励因素和抑制因素，以改善患者教育。方法采用疾病控制中心COVID-19疫苗信心：快速社区评估的问题进行自愿匿名调查。问题包括人口统计、疫苗接种状况和意见，采用多项选择和自由回答形式。该调查于2023年7月发放，为期一个月。结果共有127例SOTRs应答，包括18岁及以上接受心脏（12.6%）、肺（37.01%）、肝（31.5%）、肾（11.81%）和肝肾合一（7.09%）移植的患者。绝大多数应答者（97.64%）接受了一次系列疫苗接种。在接种者中，68.55%的人接受了二价加强疫苗接种，32.28%的人接受了第二次加强疫苗接种。最大的激励因素是“保护自己的健康”（84.68%）、“保护家人和朋友的健康”（66.13%）和“保护社区的健康”（36.29%）。只有3个sotr未接种疫苗，他们都报告说他们觉得疫苗不安全。结论绝大多数SOTRs接种了COVID-19疫苗，以保护自己和他人的健康，但少数人对接种加强疫苗犹豫不决。针对这些问题进行患者教育将改善对SOTR社区的保护。

{"title":"COVID-19 vaccine evaluation among solid organ transplant recipients at a single academic center","authors":"Kristen Lay , Marina Feffer , David Slade , Fritzie S. Albarillo","doi":"10.1016/j.tpr.2025.100174","DOIUrl":"10.1016/j.tpr.2025.100174","url":null,"abstract":"<div><h3>Background</h3><div>Solid organ transplant recipients (SOTRs) may have a higher risk of serious disease and death due to COVID-19. It is necessary to determine the main motivators and demotivators for SOTRs to receive COVID-19 vaccinations to improve patient education.</div></div><div><h3>Methods</h3><div>A voluntary and anonymous survey was created using questions adopted from the Center for Disease Control COVID-19 Vaccine Confidence: Rapid Community Assessment. Questions included demographics, vaccination status and opinions in multiple choice and free response format. The survey was distributed in July 2023 and was open for one month.</div></div><div><h3>Results</h3><div>A total of 127 SOTRs responded which included patients 18 years and older who received one of the following transplants: heart (12.6 %), lung(s) (37.01 %), liver (31.5 %), kidney (11.81 %), and liver and kidney (7.09 %). The overwhelming majority of respondents received a primary vaccination series (97.64 %). Among the vaccinated, 68.55 % received a bivalent booster vaccination and 32.28 % have received a second booster vaccination. The greatest motivating factors among vaccinated were “protecting my health” (84.68 %) “protecting the health of family and friends” (66.13 %), and “to protect the health of the community” (36.29 %). Only 3 SOTRs were unvaccinated, all of whom reported that they felt the vaccine was unsafe.</div></div><div><h3>Conclusion</h3><div>While the overwhelming majority of SOTRs were vaccinated against COVID-19 to protect their health and the health of others, a minority have hesitations about receiving booster vaccinations. Targeting patient education towards these concerns will improve the protection of the SOTR community.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 2","pages":"Article 100174"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xenotransplantation: The next quarter century 异种移植：下一个四分之一个世纪

Q4 Medicine

Transplantation Reports

Pub Date : 2025-06-01 Epub Date: 2025-03-17 DOI: 10.1016/j.tpr.2025.100177

A. Joseph Tector , Matt Tector , Rodrigo Vianna , Andrew Adams

Transplantation has become a preferred therapy for the treatment of end stage organ failure, improving the quality and duration of recipients lives. The major limitation of organ transplantation is the shortage of suitable donor organs available for clinical use. Xenotransplantation using genetically modified pig organs could provide an unlimited source of organs, allowing all patients in need to receive a transplant in a timely fashion. Xenotransplantation was limited to the experimental realm because of the presence of anti-pig antibodies that are present in the blood of every human (1, 2).

The development of genetic engineering tools, especially CRISPR/Cas9 and somatic cell nuclear transfer made it possible to create pigs missing key glycan pig antigens so that the antibodies did not bind to the new pig (3-5). Preclinical results using kidneys from new donor pigs has improved to the point where nonhuman primate recipients are living for more than 4 years (Andrew Adams personal communication). The improvements in survival seen in preclinical models has led to clinical attempts at heart and kidney xenotransplantation (6, 7). Thus far in the first 5 clinical xenotransplant cases success has been modest, with only one graft (kidney) functioning past 60 days to date. The other patients receiving pig xenografts (2 hearts and 2 kidneys) succumbed to early antibody mediated rejection (AMR) (7-9). Nevertheless, the developments in preclinical and compassionate use xenotransplantation have resulted in the first FDA approved clinical trial with renal xenotransplantation. This article will deal with the issues that are likely to be the focus of the next 25 years with regards to development of clinical xenotransplantation.

移植已成为治疗终末期器官衰竭的首选治疗方法，提高了受者的生活质量和寿命。器官移植的主要限制是缺乏适合临床使用的供体器官。使用转基因猪器官的异种移植可以提供无限的器官来源，使所有需要移植的患者都能及时接受移植。异种移植被限制在实验领域，因为每个人的血液中都存在抗猪抗体（1,2）。基因工程工具的发展，特别是CRISPR/Cas9和体细胞核移植，使得制造出缺少关键糖聚糖猪抗原的猪成为可能，这样抗体就不会与新猪结合（3-5）。使用新供体猪的肾脏的临床前结果已经得到改善，非人类灵长类动物受体的寿命超过4年（Andrew Adams个人通信）。在临床前模型中观察到的生存率的提高导致了心脏和肾脏异种移植的临床尝试（6,7）。到目前为止，在前5例临床异种移植病例中，成功的情况并不多，迄今为止只有一例移植（肾脏）功能超过60天。其他接受猪异种移植（2个心脏和2个肾脏）的患者出现早期抗体介导的排斥反应（AMR）（7-9）。尽管如此，临床前和同情使用异种移植的发展导致了第一个FDA批准的肾脏异种移植临床试验。这篇文章将处理的问题，可能是未来25年的重点，关于临床异种移植的发展。

{"title":"Xenotransplantation: The next quarter century","authors":"A. Joseph Tector , Matt Tector , Rodrigo Vianna , Andrew Adams","doi":"10.1016/j.tpr.2025.100177","DOIUrl":"10.1016/j.tpr.2025.100177","url":null,"abstract":"<div><div>Transplantation has become a preferred therapy for the treatment of end stage organ failure, improving the quality and duration of recipients lives. The major limitation of organ transplantation is the shortage of suitable donor organs available for clinical use. Xenotransplantation using genetically modified pig organs could provide an unlimited source of organs, allowing all patients in need to receive a transplant in a timely fashion. Xenotransplantation was limited to the experimental realm because of the presence of anti-pig antibodies that are present in the blood of every human (1, 2).</div><div>The development of genetic engineering tools, especially CRISPR/Cas9 and somatic cell nuclear transfer made it possible to create pigs missing key glycan pig antigens so that the antibodies did not bind to the new pig (3-5). Preclinical results using kidneys from new donor pigs has improved to the point where nonhuman primate recipients are living for more than 4 years (Andrew Adams personal communication). The improvements in survival seen in preclinical models has led to clinical attempts at heart and kidney xenotransplantation (6, 7). Thus far in the first 5 clinical xenotransplant cases success has been modest, with only one graft (kidney) functioning past 60 days to date. The other patients receiving pig xenografts (2 hearts and 2 kidneys) succumbed to early antibody mediated rejection (AMR) (7-9). Nevertheless, the developments in preclinical and compassionate use xenotransplantation have resulted in the first FDA approved clinical trial with renal xenotransplantation. This article will deal with the issues that are likely to be the focus of the next 25 years with regards to development of clinical xenotransplantation.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 2","pages":"Article 100177"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-target combination of antibiotics as salvage therapy for severe infection caused by pan-resistant Burkholderia cenocepacia following lung transplantation 多靶点联合抗生素抢救治疗肺移植术后广泛耐药结核杆菌严重感染

Q4 Medicine

Transplantation Reports

Pub Date : 2025-02-01 Epub Date: 2024-12-16 DOI: 10.1016/j.tpr.2024.100170

Nadim Cassir , Benjamin Coiffard , Linda Hadjadj , Julien Bermudez , Liliane Okdah , Lucile Ailhaud , Sophie Alexandra Baron , Martine Reynaud-Gaubert , Xavier Benoit D'Journo , Sami Hraiech , Jean-Marc Rolain

Burkholderia cepacia complex (Bcc) is an important group of opportunistic pathogens most frequently affecting patients with cystic fibrosis and responsible for life-threatening infections. Therapeutic options are limited owing to high levels of resistance of the organism, either intrinsic or acquired, to many antimicrobial agents. We describe here the successful treatment of a patient with cystic fibrosis who developed post-transplant lung abscesses and sternal osteitis caused by pan-resistant Burkholderia cenocepacia. He was treated with a combination of ceftazidime-avibactam, ciprofloxacin, meropenem, minocycline, sulfadiazine, and tobramycin. Repurposing multitarget drugs including old and new antibiotics, and their combinations with synergistic effects is a promising strategy to overcome clinical therapeutic impasses with difficult-to-treat-resistance (DTR) bacteria.

洋葱伯克霍尔德菌复合体（Bcc）是一组重要的机会性病原体，最常影响囊性纤维化患者，并导致危及生命的感染。由于该生物体对许多抗微生物药物具有高水平的内在或获得性耐药性，因此治疗选择有限。我们在这里描述了一例囊性纤维化患者的成功治疗，该患者在移植后出现肺脓肿和胸骨骨炎，这是由泛耐药伯克霍尔德菌引起的。给予头孢他啶-阿维巴坦、环丙沙星、美罗培南、米诺环素、磺胺嘧啶和妥布霉素联合治疗。包括新旧抗生素在内的多靶点药物的再利用及其协同作用是克服难治性耐药（DTR）细菌的临床治疗僵局的一种有希望的策略。

{"title":"Multi-target combination of antibiotics as salvage therapy for severe infection caused by pan-resistant Burkholderia cenocepacia following lung transplantation","authors":"Nadim Cassir , Benjamin Coiffard , Linda Hadjadj , Julien Bermudez , Liliane Okdah , Lucile Ailhaud , Sophie Alexandra Baron , Martine Reynaud-Gaubert , Xavier Benoit D'Journo , Sami Hraiech , Jean-Marc Rolain","doi":"10.1016/j.tpr.2024.100170","DOIUrl":"10.1016/j.tpr.2024.100170","url":null,"abstract":"<div><div><em>Burkholderia cepacia</em> complex (Bcc) is an important group of opportunistic pathogens most frequently affecting patients with cystic fibrosis and responsible for life-threatening infections. Therapeutic options are limited owing to high levels of resistance of the organism, either intrinsic or acquired, to many antimicrobial agents. We describe here the successful treatment of a patient with cystic fibrosis who developed post-transplant lung abscesses and sternal osteitis caused by pan-resistant <em>Burkholderia cenocepacia.</em> He was treated with a combination of ceftazidime-avibactam, ciprofloxacin, meropenem, minocycline, sulfadiazine, and tobramycin. Repurposing multitarget drugs including old and new antibiotics, and their combinations with synergistic effects is a promising strategy to overcome clinical therapeutic impasses with difficult-to-treat-resistance (DTR) bacteria.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 1","pages":"Article 100170"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emergent management of severe post-TIPS bleed in patient with end-stage liver disease and coronary artery disease 终末期肝病和冠状动脉疾病患者tips术后严重出血的紧急处理

Q4 Medicine

Transplantation Reports

Pub Date : 2025-02-01 Epub Date: 2024-12-13 DOI: 10.1016/j.tpr.2024.100168

Mohammad Arammash , Barbara Hamilton , Charles Rickert

Liver transplantation has become widely available but remains a high-risk operation not suitable in the presence of severe comorbidities. Pre-operative planning to address potential challenges is key to ensuring optimal outcomes. In this report, we highlight a challenging clinical situation in which a patient with severe portal vein thrombosis and coronary artery disease developed a significant bleed post TIPS, necessitating emergent ligation of the portal structures and urgent liver transplantation. The patient successfully underwent coronary artery bypass grafting after liver transplantation. This case demonstrates an unconventional method for remediating inaccessible portal vein hemorrhage secondary to transjugular intrahepatic portosystemic shunting and the ability to perform coronary artery bypass grafting post-liver transplantation.

肝移植已广泛应用，但仍是一种高风险手术，不适合存在严重的合并症。术前计划应对潜在挑战是确保最佳结果的关键。在这篇报告中，我们强调了一个具有挑战性的临床情况，患者有严重的门静脉血栓形成和冠状动脉疾病，在TIPS后出现严重出血，需要紧急结扎门静脉结构和紧急肝移植。患者肝移植后成功行冠状动脉旁路移植术。本病例展示了一种非常规的方法来修复经颈静脉肝内门静脉分流继发的无法到达的门静脉出血，以及肝移植后进行冠状动脉旁路移植术的能力。

引用次数: 0

Observed vs. Expected organs transplanted in pediatric donors at Saint Francis hospital 圣弗朗西斯医院儿童供体观察到的与预期的器官移植

Q4 Medicine

Transplantation Reports

Pub Date : 2025-02-01 Epub Date: 2024-12-13 DOI: 10.1016/j.tpr.2024.100169

R. Goodwin , K. Champlin , B. Cloud , C. Yancey , C. Hendrix , S. Parikh , M. Howell , R. Ketcham , A. Milam , B. Nave , T. Campbell , M. Cheruvu

Purpose

This retrospective case study aims to clarify the roles played by various factors in determining the actual versus expected number of organs procured from pediatric trauma patients.

Significance

Trauma patients often have injuries so extensive that there is no hope of recovery. However, if they are stabilized, they may be able to save lives through organ donation. The more organs are procured, the more lives may be saved.

Strategy and Implementation

In this retrospective study, we reviewed the records of pediatric organ donors from Saint Francis Children's Hospital from 2018 to 2022 and identified seven interesting cases involving children younger than 15 years old that showed the actual and expected numbers of organs transplanted. We examined the number of organs that we expected to transplant compared with how many organs were actually transplanted and which clinical data may have affected the ability to transplant.

Outcomes

The data analysis included but was not limited to the observed-to-expected ratio, donor management goals, hospital lab and biometric values before the time of referral, cause of death, age, sex, race, body mass index, blood type, kidney donor profile index, referral timeliness, donation conversations, donation conversation outcomes, hospital attending, pre-mentions of donation to potential families, referral and donation milestone date-time stamps, donor outcomes, organs recovered, organs transplanted, organs discarded, organs submitted to research, and survey responses. Based on the seven identified cases, this study shows that an observed-to-expected ratio greater than 1 is achievable.

Implications for Practice

Identifying factors that affect increased observed organ procurement will increase the potential of transplantable organs, thus leading to a higher number of lives saved.

目的：本回顾性病例研究旨在阐明各种因素在决定从儿童创伤患者获得的实际器官数量与预期器官数量之间的作用。意义创伤患者的损伤通常非常大，以至于没有康复的希望。然而，如果病情稳定下来，他们可能会通过器官捐赠来挽救生命。获得的器官越多，就能挽救越多的生命。策略与实施在这项回顾性研究中，我们回顾了圣弗朗西斯儿童医院2018年至2022年的儿童器官捐赠者记录，并确定了7例涉及15岁以下儿童的有趣病例，这些病例显示了实际和预期的器官移植数量。我们检查了我们期望移植的器官数量与实际移植的器官数量以及哪些临床数据可能影响移植能力。数据分析包括但不限于：观察预期比、献血者管理目标、转诊前的医院实验室和生物特征值、死亡原因、年龄、性别、种族、体重指数、血型、肾脏献血者概况指数、转诊及时性、捐赠谈话、捐赠谈话结果、医院就诊、向潜在家庭预先提及捐赠、转诊和捐赠里程碑日期-时间标记、献血者结果、器官恢复、移植的器官，丢弃的器官，用于研究的器官，以及调查结果。基于所确定的七个案例，本研究表明，观察到的期望比大于1是可以实现的。对实践的影响识别影响观察到的器官获取增加的因素将增加可移植器官的潜力，从而导致更多的生命得到挽救。

{"title":"Observed vs. Expected organs transplanted in pediatric donors at Saint Francis hospital","authors":"R. Goodwin , K. Champlin , B. Cloud , C. Yancey , C. Hendrix , S. Parikh , M. Howell , R. Ketcham , A. Milam , B. Nave , T. Campbell , M. Cheruvu","doi":"10.1016/j.tpr.2024.100169","DOIUrl":"10.1016/j.tpr.2024.100169","url":null,"abstract":"<div><h3>Purpose</h3><div>This retrospective case study aims to clarify the roles played by various factors in determining the actual versus expected number of organs procured from pediatric trauma patients.</div></div><div><h3>Significance</h3><div>Trauma patients often have injuries so extensive that there is no hope of recovery. However, if they are stabilized, they may be able to save lives through organ donation. The more organs are procured, the more lives may be saved.</div></div><div><h3>Strategy and Implementation</h3><div>In this retrospective study, we reviewed the records of pediatric organ donors from Saint Francis Children's Hospital from 2018 to 2022 and identified seven interesting cases involving children younger than 15 years old that showed the actual and expected numbers of organs transplanted. We examined the number of organs that we expected to transplant compared with how many organs were actually transplanted and which clinical data may have affected the ability to transplant.</div></div><div><h3>Outcomes</h3><div>The data analysis included but was not limited to the observed-to-expected ratio, donor management goals, hospital lab and biometric values before the time of referral, cause of death, age, sex, race, body mass index, blood type, kidney donor profile index, referral timeliness, donation conversations, donation conversation outcomes, hospital attending, pre-mentions of donation to potential families, referral and donation milestone date-time stamps, donor outcomes, organs recovered, organs transplanted, organs discarded, organs submitted to research, and survey responses. Based on the seven identified cases, this study shows that an observed-to-expected ratio greater than 1 is achievable.</div></div><div><h3>Implications for Practice</h3><div>Identifying factors that affect increased observed organ procurement will increase the potential of transplantable organs, thus leading to a higher number of lives saved.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 1","pages":"Article 100169"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143182233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing deep variant phenotyping of mitochondrial enzyme complexes for precision medicine in allogeneic hematopoietic stem-cell transplantation 推进线粒体酶复合物的深度变异表型分析，为异基因造血干细胞移植的精准医学提供依据

Q4 Medicine

Transplantation Reports

Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI: 10.1016/j.tpr.2025.100171

Jing Dong , Michael T. Zimmermann , Neshatul Haque , Shahram Arsang-Jang , Wael Saber , Xiaowu Gai , Raul Urrutia

Allogeneic hematopoietic stem-cell transplantation (allo-HCT), an early developed methodology for precision medicine, remains the only curative therapy for myelodysplastic syndromes (MDS). However, allo-HCT carries significant risks of morbidity and mortality due to relapse and transplant-related complications. Recurrent mutations in mitochondrial DNA (mtDNA) have been identified as significant prognostic indicators for MDS outcomes following allo-HCT. However, the biological mechanisms of mtDNA mutations remain unclear. Thus, here we performed deep variant phenotyping by integrating computational biophysics and structural genomics approaches to reveal the molecular mechanisms underlying mtDNA variant dysfunction. This emerging genomics discipline employs structural models, molecular mechanic calculations, and accelerated molecular dynamic simulations to analyze gene products, focusing on their structures and motions that determine their function. We applied this methodology on the variants in the mitochondria-encoded complex I genes that are associated with MDS pathobiology and prognosis after allo-HCT. Our results demonstrate that this approach significantly outperforms conventional analytical methods, providing enhanced and more accurate information to support the potential pathogenicity of these variants and better infer their dysfunctional mechanisms. We conclude that the adoption and further expansion of computational structural genomics approaches, as applied to the mitochondrial genome, have the potential to significantly increase our understanding of molecular mechanisms underlying the disease. Our study lays a foundation for translating mitochondrial biology into clinical applications, which will advance the integration of precision medicine with allo-HCT.

同种异体造血干细胞移植（allo-HCT）是一种早期发展的精准医学方法，仍然是治疗骨髓增生异常综合征（MDS）的唯一治疗方法。然而，由于复发和移植相关并发症，同种异体hct具有显著的发病率和死亡率风险。线粒体DNA （mtDNA）的复发性突变已被确定为异基因hct后MDS结果的重要预后指标。然而，mtDNA突变的生物学机制尚不清楚。因此，在这里，我们通过整合计算生物物理学和结构基因组学方法来进行深度变异表型分析，以揭示mtDNA变异功能障碍的分子机制。这门新兴的基因组学学科采用结构模型、分子力学计算和加速分子动力学模拟来分析基因产物，重点研究决定其功能的结构和运动。我们将这种方法应用于线粒体编码复合体I基因的变异，这些基因与异基因hct后MDS的病理生物学和预后相关。我们的研究结果表明，这种方法明显优于传统的分析方法，提供了增强和更准确的信息来支持这些变异的潜在致病性，并更好地推断它们的功能失调机制。我们的结论是，计算结构基因组学方法的采用和进一步扩展，如应用于线粒体基因组，有可能显著增加我们对疾病分子机制的理解。我们的研究为线粒体生物学转化为临床应用奠定了基础，将推动精准医学与同种异体hct的融合。

{"title":"Advancing deep variant phenotyping of mitochondrial enzyme complexes for precision medicine in allogeneic hematopoietic stem-cell transplantation","authors":"Jing Dong , Michael T. Zimmermann , Neshatul Haque , Shahram Arsang-Jang , Wael Saber , Xiaowu Gai , Raul Urrutia","doi":"10.1016/j.tpr.2025.100171","DOIUrl":"10.1016/j.tpr.2025.100171","url":null,"abstract":"<div><div>Allogeneic hematopoietic stem-cell transplantation (allo-HCT), an early developed methodology for precision medicine, remains the only curative therapy for myelodysplastic syndromes (MDS). However, allo-HCT carries significant risks of morbidity and mortality due to relapse and transplant-related complications. Recurrent mutations in mitochondrial DNA (mtDNA) have been identified as significant prognostic indicators for MDS outcomes following allo-HCT. However, the biological mechanisms of mtDNA mutations remain unclear. Thus, here we performed deep variant phenotyping by integrating computational biophysics and structural genomics approaches to reveal the molecular mechanisms underlying mtDNA variant dysfunction. This emerging genomics discipline employs structural models, molecular mechanic calculations, and accelerated molecular dynamic simulations to analyze gene products, focusing on their structures and motions that determine their function. We applied this methodology on the variants in the mitochondria-encoded complex I genes that are associated with MDS pathobiology and prognosis after allo-HCT. Our results demonstrate that this approach significantly outperforms conventional analytical methods, providing enhanced and more accurate information to support the potential pathogenicity of these variants and better infer their dysfunctional mechanisms. We conclude that the adoption and further expansion of computational structural genomics approaches, as applied to the mitochondrial genome, have the potential to significantly increase our understanding of molecular mechanisms underlying the disease. Our study lays a foundation for translating mitochondrial biology into clinical applications, which will advance the integration of precision medicine with allo-HCT.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 1","pages":"Article 100171"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143182232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary central nervous system post-transplant lymphoproliferative Disorder in a lung transplant recipient despite reduction of immunosuppression 肺移植受者的原发性中枢神经系统移植后淋巴增生性疾病，尽管免疫抑制减少

Q4 Medicine

Transplantation Reports

Pub Date : 2025-02-01 Epub Date: 2025-01-25 DOI: 10.1016/j.tpr.2025.100172

K Afshar , JM Kozuch , M Don , C Gaissert , E Golts

Lymphomas arising in the setting of immune deficiency and/or dysregulation, also known as post-transplant lymphoproliferative disorder (PTLD) is frequently associated with immunosuppressive therapies and the Epstein Barr Virus after solid organ transplantation. Primary central nervous system PTLD (PCNS-PTLD) is extremely rare. Our group presents only the third reported case of PCNS-PTLD in the setting of lung transplantation.

在免疫缺陷和/或失调的情况下出现的淋巴瘤，也称为移植后淋巴组织增生性疾病（PTLD），通常与免疫抑制疗法和实体器官移植后的爱泼斯坦巴氏病毒有关。原发性中枢神经系统淋巴增生性疾病（PCNS-PTLD）极为罕见。我们的研究小组仅报告了第三例肺移植中的 PCNS-PTLD 病例。

引用次数: 0